Germany Licenses
Found this and pasted a google translate below https://www.handelsblatt.com/technik/forschung-innovation/aphria-aurora-und-demecan-die-cannabis-anbauer-in-deutschland-stehen-fest-vorerst/24181804.html The cannabis growers in Germany are stuck - for the time being by Maike Telgheder Two Canadian companies and a German start-up are awarded a contract for medical cannabis cultivation. The decision is still not final. The cannabis growers in Germany are stuck. Source: AP FrankfurtThe additions for the cultivation of medical cannabis in Germany have been granted: The German subsidiaries of the Canadian companies Aphria and Aurora as well as the Berlin-based company Demecan, founded in 2017, will receive the additions for the total of 13 lots. The Handelsblatt learned from industry circles. Aphria Germany confirmed to Handelsblatt that it had won five of the 13 lots. Aurora Germany and Denecan initially did not comment. Aurora should also have received five lots, according to industry information, Demecan three. "We are very pleased to have been awarded the contract for five lots and to be able to build up medicinal-grade cannabis in Germany with our experience," says Aphria-Germany Managing Director Hendrick Knopp. Aphria is one of Canada's leading cannabis companies. In Germany, Aphria wants to set up its business on two pillars: Aphria wants to offer three varieties of flowers by cultivating them locally, other varieties of medicinal cannabis can be imported from Canada and, in the future, also from the plants in Denmark. Aphria Germany will grow the cannabis plants in its 8,000 square meter facility in Neumnster, where medical chili, which is also needed for heat patches, is still growing. Thirty-three bidders and consortia had submitted bids in the tendering process of the Federal Institute for Drugs and Medical Devices (Bfarm). The tender includes 10,400 kilograms of cannabis, spread over four years with 2,600 kilograms each. The Federal Institute expects the first harvest for the 4th quarter of 2020. If necessary, additional medical cannabis can be imported. However, the final decision for the cannabis growers in Germany is not yet. For ten days can be filed against the award of each lot. Because of these procedural reasons, the Bfarm, according to a spokesman, currently does not comment on the award of the contract. The use of cannabis for therapeutic purposes has been permitted in Germany since March 2017 for serious illnesses. According to the law, cannabis must also be reimbursed as a medicine by the statutory health insurance if other therapeutic options are exhausted. Current estimates are based on around 40,000 cannabis patients in Germany. There is no such thing as national statistics. Last year, according to the statistics of the Central Association of Statutory Health Insurance Funds, more than 185,000 prescriptions were issued for cannabis-containing preparations, flowers and finished medicinal products. The regulations add up to a gross turnover of 74 million euros. The more than 71,000 orders for flowers make up nearly 33 million euros. For how much sales the lots of tender, are Aphria Germany boss Knopp not betrayed. It is certain that the three growers in Germany, who have received the supplements, can count on millions in sales. One lot stands for an annual amount of 200 kilograms of cannabis flowers, five lots for one ton. The manufacturer's prices for cannabis are according to information from industry circles on the world market between 1.50 and about eight euros per gram of cannabis. The prices for the tender in Germany are likely to be below the 5 mark. Based on a price of four euros, the five lots represent a turnover of four million euros per year or 16 million euros for the tendering period of four years. A first call for tenders for the cultivation of medicinal cannabis in Germany was canceled by the Bfarm last year because the Dusseldorf Higher Regional Court had followed the opinion of a plaintiff company that the deadline after a procedural change had not been sufficient. According to industry sources, Aphria has filed a lawsuit against the second bid. However, as the company has now been awarded a contract, the plea is removed and insiders expect the company to withdraw its claim. Aphria herself does not want to comment on the subject. In the future, the agency set up by the Bfarm will sell medical cannabis made in Germany. It will purchase and take possession of the blooms in accordance with United Nations prescriptions on narcotic drugs and sell them to manufacturers of cannabis medicines, wholesalers or pharmacies. The Federal Institute may not achieve profits or surpluses.